Table 3 Selected outcomes of allo-SCT... | American Society of Hematology

Table 3

Selected outcomes of allo-SCT for relapsed or refractory FL

Series	Reference	Preparative regimen	No. of patients	MRD (%)	Prior rituximab	NRM (%)	NRM timepoint (y)	P	PFS/EFS (%)	PFS timepoint (y)	P	OS (%)	OS timepoint (y)	P
IBMTR	13	MA	176	100	NR	30	5		45%	5		51	5
CIBMTR	58	MA	120	100	26	25	3		67	3		62	3
CIBMTR	58	RIC	80	100	45	28			55			71
EBMT	54	RIC ATG	46	100	NR	18	3	NS	55	3	.015	70	3	NS
		RIC, alemtuzumab	42	100	NR	18			44			68
		RIC, no TCD	76	100	NR	17			67			74
NCCN	44	Allo-SCT	48	63	100	24	3		52	3		61	3
EBMT	53	RIC	149	80	62	22	3		57	5		67	5
CIBMTR/EBMT FL1/2	39	RIC	268	53	100	26	5		58	5		66	5
CIBMTR/EBMT FL3	40	RIC	61	59	100	27	5		51	5		54	5

Series	Reference	Preparative regimen	No. of patients	MRD (%)	Prior rituximab	NRM (%)	NRM timepoint (y)	P	PFS/EFS (%)	PFS timepoint (y)	P	OS (%)	OS timepoint (y)	P
IBMTR	13	MA	176	100	NR	30	5		45%	5		51	5
CIBMTR	58	MA	120	100	26	25	3		67	3		62	3
CIBMTR	58	RIC	80	100	45	28			55			71
EBMT	54	RIC ATG	46	100	NR	18	3	NS	55	3	.015	70	3	NS
		RIC, alemtuzumab	42	100	NR	18			44			68
		RIC, no TCD	76	100	NR	17			67			74
NCCN	44	Allo-SCT	48	63	100	24	3		52	3		61	3
EBMT	53	RIC	149	80	62	22	3		57	5		67	5
CIBMTR/EBMT FL1/2	39	RIC	268	53	100	26	5		58	5		66	5
CIBMTR/EBMT FL3	40	RIC	61	59	100	27	5		51	5		54	5

ATG, antithymocyte globulin; MA, myeloablative; MRD, matched related donor; NR, not reported; NS, not significant; TCD, T-cell depletion.